Dexcom First To CGM Reimbursement Finish Line
Executive Summary
Following a recent approval for their G5 continuous glucose monitor for use in children and adults without a finger stick, Dexcom has scored big with a new US Centers for Medicaid and Medicare Services policy that would make their CGM the first of its kind eligible for reimbursement from the agency.
You may also be interested in...
Lawsuit Seeks Expanded Medicare Reimbursement For CGM
A law firm has filed a class action suit against the US Department of Health and Human Services trying to force broader Medicare reimbursement of continuous glucose monitors. Currently, federal health programs will only cover specific types and uses of the diabetes treatment technology.
Abbott Gains Go-Ahead For First 'No-Fingerstick' CGM
Abbott Laboratories' Freestyle Libre Flash is the first continuous glucose monitoring system to gain US FDA approval that lets diabetics avoid the additional step of fingerstick calibration to measure their glucose levels, "with the wave of a mobile reader," the agency says.
Dexcom Looks To Expansion, Operational Efficiency For Rapid Growth
Continuous blood glucose monitoring specialist Dexcom has seen its sales soar from $60m to over $700m within five years or so. Company president and CEO Kevin Sayer told Medtech Insight how the company is aiming to maintain this upward trajectory with a new addition to the leadership team, increased operational efficiency and expansion into new markets.